Sequel Med Tech Inks Commercial Development Agreement With Senseonics To Integrate Sequel's twiist Automated Insulin Delivery (AID)

+2.10%

Senseonics Holdings, Inc.

SENS

0.00

Sequel Med Tech Inks Commercial Development Agreement With Senseonics To Integrate Sequel's twiist Automated Insulin Delivery (AID)

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Executive Vice President of Enterprise Operations Gregory Smith Sold A Bunch Of Shares In Medtronic

ICU Medical (ICUI): Evaluating Valuation Following Recent 15% Share Price Rebound

Waters Proposed Acquisition Of Becton, Dickinson and Company's Biosciences And Diagnostic Solutions Businesses Gets European Commission Approval

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

How Investors May Respond To CONMED (CNMD) Analyst Upgrades and Raised Earnings Estimates

IDEXX Laboratories (IDXX): Assessing Valuation Following Strong Earnings Beat and Updated Growth Guidance

Insiders At LeMaitre Vascular Sold US$8.9m In Stock, Alluding To Potential Weakness

UPDATE 2-Serbia's Russia-owned oil refinery faces shutdown as US sanctions bite, president says